Global Kaposi Sarcoma Market 2017-2021 - Product Image

Global Kaposi Sarcoma Market 2017-2021

  • ID: 4231739
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 7

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly and Pfizer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • MORE
Kaposi sarcoma is a multicentral tumor. The tumor is caused by Kaposi sarcoma-associated herpesvirus (KSHV) also known as human herpesvirus 8 (HHV8). It can occur as endemic, classic, epidemic, and iatrogenic forms. Epidemic or acquired immune deficiency syndrome (AIDS)-associated form of treatment is one of the most prevalent types followed in the treatment of Kaposi sarcoma globally. The diagnosis is done by biopsy, and major treatment types include chemotherapy, HAART, and immunotherapy. HAART is the most common type of treatment due to a high prevalence rate of AIDS-associated Kaposi sarcoma.

The analysts forecast the global Kaposi sarcoma market to grow at a CAGR of 2.46% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global Kaposi sarcoma market for 2017-2021. To calculate the market size, the report considers the sales of both generic as well as branded drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Kaposi Sarcoma Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Bristol-Myers Squibb
- GlaxoSmithKline
- Johnson & Johnson
- Merck

Other prominent vendors
- Eli Lilly
- Pfizer

Market drivers
- Rising number of organ transplants
- For a full, detailed list, view the full report

Market challenges
- High cost of treatment
- For a full, detailed list, view the full report

Market trends
- Increasing consolidation in the cancer treatment market
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 7

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly and Pfizer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of Kaposi sarcoma

PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by type of treatment
  • HAART
  • Chemotherapy
  • Immunotherapy
PART 09: Geographical segmentation
  • Kaposi sarcoma market in Americas
  • Kaposi sarcoma market in EMEA
  • Kaposi sarcoma market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Increasing consolidation in the cancer treatment market
  • Emphasis on combination therapy
  • Application of Kaposi sarcoma-specific treatment (local treatment)
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits

Exhibit 01: Types of Kaposi sarcoma
Exhibit 02: Treatment overview for Kaposi sarcoma
Exhibit 03: Global Kaposi sarcoma market snapshot
Exhibit 04: Global Kaposi sarcoma market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global Kaposi sarcoma market
Exhibit 06: Five forces analysis
Exhibit 07: Key pipeline candidates by sponsors/collaborators
Exhibit 08: Pipeline analysis
Exhibit 09: Segmentation of global Kaposi sarcoma market by type of treatment
Exhibit 10: Combination antiretroviral therapy (ART): Common inclusions
Exhibit 11: Global Kaposi sarcoma HAART therapy market 2016-2021 ($ millions)
Exhibit 12: Change in HIV/AIDS population 2010-2015
Exhibit 13: Major types of chemotherapy
Exhibit 14: Global Kaposi sarcoma chemotherapy market 2016-2021 ($ millions)
Exhibit 15: Advantages and disadvantages of chemotherapy
Exhibit 16: Global Kaposi sarcoma immunotherapy market 2016-2021 ($ millions)
Exhibit 17: Segmentation of global Kaposi sarcoma market based on geography 2016 and 2021
Exhibit 18: Kaposi sarcoma market revenue by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: Kaposi sarcoma market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Kaposi sarcoma market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Kaposi sarcoma market in APAC 2016-2021 ($ millions)
Exhibit 25: Percentage distribution of organ transplants in US 1988-2016
Exhibit 26: Total global population living with HIV/AIDS (million)
Exhibit 27: Global number of people living with and died due to AIDS/HIV 2014-2015 (million)
Exhibit 28: Kaposi sarcoma: Before and after the AIDS epidemic in US
Exhibit 29: Competitive analysis of global Kaposi sarcoma market
Exhibit 30: Bristol-Myers Squibb: Key highlights
Exhibit 31: Bristol-Myers Squibb: Strength assessment
Exhibit 32: Bristol-Myers Squibb: Strategy assessment
Exhibit 33: Bristol-Myers Squibb: Opportunity assessment
Exhibit 34: GlaxoSmithKline: Key highlights
Exhibit 35: GlaxoSmithKline: Strength assessment
Exhibit 36: GlaxoSmithKline: Strategy assessment
Exhibit 37: GlaxoSmithKline: Opportunity assessment
Exhibit 38: Johnson & Johnson: Key highlights
Exhibit 39: Johnson & Johnson: Strength assessment
Exhibit 40: Johnson & Johnson: Strategy assessment
Exhibit 41: Johnson & Johnson: Opportunity assessment
Exhibit 42: Merck: Key highlights
Exhibit 43: Merck: Strength assessment
Exhibit 44: Merck Strategy assessment
Exhibit 45: Merck: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 7

Loading
LOADING...

4 of 7

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly and Pfizer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • MORE
New Report Released: - Global Kaposi Sarcoma Market 2017-2021.

The author of the report recognizes the following companies as the key players in the global Kaposi sarcoma market: Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, and Merck.

Other Prominent Vendors in the market are: Eli Lilly and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increasing consolidation in the cancer treatment market. Past several years have witnessed significant consolidation in the cancer treatment industry. There can be seen a trend of movement of cancer treatment from clinics to hospitals. Studies have shown that there is a rise in a number of oncology clinics that got acquired by hospitals.”

According to the report, one of the major drivers for this market is rising number of organ transplants. Organ transplant is the transfer of organs from donor to recipient. It is done with the aim of restoring the functions of the body. In many occasions, organ transplantation is the only treatment option left at the end stage of organ failures such as heart or liver failure. The organ transplant process has rapidly increased during the last few years. The rising improvement rate in the post-transplant outcome and increasing success rate has led to high adoption for the organ transplant.

Further, the report states that one of the major factors hindering the growth of this market is high cost of treatment. The high cost of treatment is a major problem for the cancer patients. The majority of the cancer treatments available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. This can be understood from the fact that an average US family earns around $50,000-52,000 annually. The cancer treatment can cost up to $125,000 per annum. An insured person has an out-of-pocket expense of around $20,000-$30,000; it is clearly more than half of the family’s income. This is a huge problem faced by population across the world, and as a result, a large number of individuals either compromise or skip the prescribed treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 7
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Eli Lilly and Pfizer
Note: Product cover images may vary from those shown
6 of 7
7 of 7
Note: Product cover images may vary from those shown
Adroll
adroll